LEADER 03708nam  22006254a 450 
001 9910808219803321
005 20200520144314.0
010   $a600-00-0515-6
010   $a9786610505364
010   $a1-280-50536-2
010   $a1-60129-451-4
035   $a(CKB)111087027618448
035   $a(OCoLC)53017729
035   $a(CaPaEBR)ebrary10116449
035   $a(SSID)ssj0000218144
035   $a(PQKBManifestationID)11217602
035   $a(PQKBTitleCode)TC0000218144
035   $a(PQKBWorkID)10214391
035   $a(PQKB)11091629
035   $a(MiAaPQ)EBC267521
035   $a(Au-PeEL)EBL267521
035   $a(CaPaEBR)ebr10116449
035   $a(CaONFJC)MIL50536
035   $a(OCoLC)437171326
035   $a(EXLCZ)99111087027618448
100   $a20011105d2002      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aParkinson's disease /$fedited by E. Ronken and G.J.M. van Scharrenburg
205   $a1st ed.
210   $aAmsterdam ;$aWashington, DC $cIOS Press$dc2002
215   $a1 online resource (168 p.)
225 1 $aSolvay Pharmaceuticals Conferences,$x1566-7685 ;$vv. 1
300   $a"The First Solvay Pharmaceuticals Conference on "Parkinson's Disease" was held in Como from October 25 to 27, 2000"--Pref.
311   $a1-58603-207-0 
311   $a0-585-45882-0 
320   $aIncludes bibliographical references and index.
327   $aCover -- Title page -- Preface -- List of Contributors -- Contents -- Conference Preface -- Key-note lecture - Movement Disorders: An Overview -- Part I: Parkinson's Disease - Symptoms, Models and Treatment -- Neurochemical Changes in Parkinson's Disease -- Psychosis and Depression in Parkinson's Disease -- Experimental Models of Parkinson's Disease -- SLV308: A Novel Antiparkinsonian Agent with Antidepressant and Anxiolytic Properties -- Adenosine A[sub(2A)] Receptor Antagonists and Parkinson's Disease -- Part II: Understanding and Influencing Neuro-Degeneration -- Bioenergetics in Neurodegeneration -- Neuronal Cell Death and Apoptosis in Neurodegenerative Diseases -- Animal Models of Neurodegeneration in Parkinson's Disease -- Parkinsonian Features of the Ataxia-Telangiectasia and of the Atm-Deficient Mouse -- Neuroprotection in Parkinson's Disease through Selective Gene Induction -- Part III: Towards Neuroprotective Efficacy -- The RET-Dependent Neuroprotective Effects of GDNF are Mediated by Activation of Proteinkinase B (PKB)/AKT -- An Immortalized Neuronal Cell Line Derived from the Substantia Nigra of an Adult Rat: Application to Cell Transplant Therapy -- Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease Prevents Neurodegeneration -- Design of Clinical Studies for Neuroprotective Efficacy -- Regulation of Glial Cell Line-Derived Neurotrophic Factor (GDNF) for Dopamine Conservation in Models for Parkinson's Disease -- Concluding Remarks -- Author Index -- A -- B -- C -- D -- E -- F -- H -- J -- K -- L -- M -- N -- O -- P -- R -- S -- T -- V -- W.
330   $aThis volume contains the proceedings of the first Solvay Pharmaceuticals Research Symposium, and is dedicated to Parkinson's disease. It provides an update of clinical and preclinical research.
410  0$aSolvay Pharmaceuticals Conferences ;$vv. 1.
606   $aParkinson's disease$vCongresses
615  0$aParkinson's disease
676   $a616.8/33
701   $aRonken$b E$01674979
701   $aScharrenburg$b G. J. M. van$01674980
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910808219803321
996   $aParkinson's disease$94040139
997   $aUNINA